Nanoparticle-mediated drug delivery systems or ligand-targeted approaches (e.g., using MUC16-binding peptides) could enhance the selective inhibition of MSLN at the tumor site, minimizing off-target effects [58,59]. Here, MUC16 is linked to neoplasm.